-
Safety
-
Resources for You
-
-
MedWatch: The FDA Safety Information and Adverse Event Reporting Program
![]() |
Your FDA gateway for finding clinically important safety information and reporting serious problems with human medical products. |
| The MedWatch web site was modified as part of the redesign of the entire FDA web site. FDA is interested in your comments about these changes and your suggestions for improving the functionality of the site. Our goal is to offer quick and direct access to new, clinically important safety information or to report a suspected serious adverse event. We welcome your suggestions on how to make that process better. |
-
What's New
- BiPAP Focus Non-Invasive Ventilator System, Respironics California
Class I Recall due to power supply failures that have occurred on some ventilators. Posted 07/09/2009 - Stealth Chocolate, Stealth Vanilla Powdered Dietary Supplement: Vital Pharmaceuticals Inc
Nationwide recall because of the potential for contamination with Salmonella. Posted 07/09/2009 - Propoxyphene-containing Products
FDA taking actions to reduce the risk of overdose in patients using pain medications that contain propoxyphene because of data linking propoxyphene and fatal overdoses. Posted 07/07/2009 - Arthroscopic Shavers: Ongoing Safety Review
Reports submitted to FDA describing instances of tissue remaining within certain arthroscopic shavers, even after the cleaning process was believed to have been completed. Posted 07/07/2009 - Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)
FDA requires new Boxed Warnings and patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms. Posted 07/01/2009 - Lantus (insulin glargine)
FDA reviewing safety data regarding possible risk for cancer in patient with diabetes. Posted 07/01/2009 - FDA Patient Safety News Video Broadcasts
July 2009 video news show for healthcare professionals, covering safety alerts, recalls, product approvals, and important tips on protecting patients. (Posted 07/01/2009) - FDA Drug Safety Newsletter
Information for healthcare professionals about the findings of selected postmarketing drug safety reviews from FDA, as well as information on important emerging drug safety issues and recently approved new molecular entities. Posted 06/26/2009
-
-
Spotlight
-
-
Recalls & Alerts
-
-
Stay Informed
-
Contact Us
- 1-800-332-1088
- 1-800-FDA-0178 Fax
-
Regular Mail: Use postage-paid FDA Form 3500
Mail to: MedWatch 5600 Fishers Lane
Rockville, MD 20852-9787
-
-
-


